Brief: Cadrenal Therapeutics Acquires VLX-1005, A First-In-Class Phase 2 12-LOX Inhibitor For Patients With Heparin-Induced Thrombocytopenia

Cadrenal Therapeutics

11/12/2025 13:07

Dec 11 (Reuters) - Cadrenal Therapeutics Inc CVKD.O:

CADRENAL THERAPEUTICS ACQUIRES VLX-1005, A FIRST-IN-CLASS PHASE 2 12-LOX INHIBITOR FOR PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

CADRENAL THERAPEUTICS INC - VERALOX ELIGIBLE FOR UPFRONT AND MILESTONE PAYMENTS

CADRENAL THERAPEUTICS INC - VERALOX ENTITLED TO ROYALTIES ON GLOBAL SALES OF ACQUIRED ASSETS UPON FUTURE COMMERCIALIZATION

Source text: ID:nGNX8s0MrV

Further company coverage: CVKD.O

 ((Reuters.Briefs@thomsonreuters.com;))